Birchview Capital’s Solid Biosciences SLDB Stock Holding History

Birchview Capital’s Portfolio SLDB Stock Details SLDB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.66M	Buy	666,196 +40,216	+6%	+$305K	3.11%	5
2026 Q1	$4.51M	Sell	625,980 -79,975	-11%	-$514K	2.57%	9
2025 Q4	$3.98M	Buy	705,955 +409,000	+138%	+$2.22M	2.33%	12
2025 Q3	$1.83M	Buy	296,955 +118,187	+66%	+$691K	1.38%	21
2025 Q2	$871K	Buy	178,768 +50,000	+39%	+$177K	0.86%	27
2025 Q1	$476K	Buy	+128,768	New	+$551K	0.41%	34
2018 Q4	–	Sell	-400	Closed	-$283K	–	55
2018 Q3	$283K	Hold	400	–	–	0.18%	45
2018 Q2	$214K	Sell	400 -933	-70%	-$287K	0.15%	44
2018 Q1	$150K	Buy	+1,333	New	+$450K	0.1%	46

Other funds holding SLDB

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Birchview Capital's SLDB Position: Q2 2026 in Review

Birchview Capital increased its Solid Biosciences (SLDB) stake by 6.4% in Q2 2026, buying an estimated $305K and bringing the position to 666,196 shares worth $6.66M. The position accounts for 3.11% of the portfolio, ranked #5.

Birchview Capital first reported a position in SLDB in Q1 2018 and has held it in 9 quarters since. 156 funds tracked by Wall St. Rank hold SLDB as of Q2 2026.

Birchview Capital held 666,196 shares of Solid Biosciences worth $6.66M as of Q2 2026.
Birchview Capital bought 40,216 Solid Biosciences shares in Q2 2026, an estimated $305K.
Solid Biosciences made up 3.11% of Birchview Capital's portfolio in Q2 2026, its #5 holding.
Birchview Capital first reported a position in Solid Biosciences in Q1 2018 and has held it in 9 quarters since.
156 funds tracked by Wall St. Rank held Solid Biosciences as of Q2 2026.

Based on Birchview Capital's 13F filing for Q2 2026, filed 14 Aug 2026.